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Early Recurrence of Cerebrovascular Events
After Transient Ischaemic Attack
To the Editor:
We read with great interest the recent article by Lisabeth et al1
regarding the stroke risk after a transient ischemic attack (TIA).
Their results are similar to those reported in the mid- and
late-1990s2,3 and considerably lower than more recent studies
reported in the UK4,5 and Canada.6 We run rapid access TIA
clinics for the assessment and investigation of individuals re-
ferred by their general practitioner following a suspected cere-
brovascular event that has not necessitated in-patient manage-
ment. During a recent audit of this service we examined the rate
of recurrent cerebrovascular events in new referrals over a
6-month period, to 2 hospitals in East Glasgow, Scotland.
Information was obtained from the referral letter, clinic letters,
health care practices, hospital records and investigating
departments.
Of 372 new referrals to the clinics, 37 (10%) did not attend,
130 (35%) had a non-cerebrovascular diagnosis, and 205 (55%)
were deemed to have suffered a probable or definite new TIA
(121 [32.5%]) or minor stroke (84 [22.5%]). There were 19
documented recurrent cerebrovascular events in this group giv-
ing a crude recurrence rate of 9% (95% CI, 5 to 13%), of which
10 cases (5%; 95% CI, 2 to 8%) were known to have occurred
within one week, and 15 (7%; 95% CI, 4 to 11%) within one
month of the initial episode.
Of the patients who had an initial diagnosis of TIA there were
17 recurrent events (14%; 95% CI 8 to 20%), with 7 cases (6%;
95% CI 1 to 10%) occurring within one week, and 13 (11%; 95%
CI 5 to 16%) within one month.
Multivariate analysis identified current cigarette smoking as
the only independent risk factor for a recurrent event.
Our findings are more similar to those of Coull et al5 and
Johnston et al6 and raise the concern that very early recurrence is
a significant problem that will continue to grow in tandem with
an ageing population. Although, it is presently unclear whether
secondary preventative measures can reduce these early recurrent
events, future research should be directed toward identifying the
medical and organizational strategies that would best reduce the
risk of such events.
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Response:
We would like to thank Drs Whitehead, McManus, McAlpine,
and Prof Langhorne for their interest in our paper. As their letter
indicates, in our paper we found stroke risk after transient
ischemic attack to be somewhat lower than recent studies on this
topic. We feel it is critically important to examine findings from
various studies using different methods and study populations to
understand the risk of stroke after TIA. To this end, our findings
provide estimates of risk from a prospective, population-based
study of stroke and TIA in an ethnically diverse community
using rigorous case ascertainment procedures to acquire all
strokes and TIAs that present for medical attention.
Lynda D. Lisabeth, PhD
Lewis B. Morgenstern, MD
Stroke Program
University of Michigan Health System
Ann Arbor, Mich
CT Perfusion Imaging in Cerebral Ischemia
To the Editor:
We read with interest the Guidelines and Recommendations
for Perfusion Imaging in Cerebral Ischemia by the Writing
Group on Perfusion Imaging, from the Council on Cardiovascu-
lar Radiology of the American Heart Association.1 The authors
have succeeded admirably in summarizing the important recent
developments of perfusion imaging and their relevance to clinical
investigations of cerebral ischemia. We have been involved in the
development of the First-Pass Bolus Tracking Methodology of CT
Perfusion for over a decade and would like to comment on a few
issues raised by the authors concerning this particular methodology.
1. Radiation dose.
The Table is a comparison of the effective dose equivalent2
(HE) of each of the three perfusion imaging methods discussed in
the Guidelines that involve the use of ionizing radiation. The
effective dose equivalents for the 2 computed tomography (CT)
techniques are estimated using the methodology published by
Huda et al 3 based on the CT dose index values published for
LightSpeed QXi scanners (General Electric Medical Systems).
For CT scanners of other models or from other manufacturers,
the values in the Table can be scaled proportionally according to
the computed tomography dose index value of the scanner
relative to the LightSpeed QXi scanner.
1
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The Table shows that CT perfusion (CTP) imaging does not
necessarily give a higher radiation dose to the subject than XeCT
and SPECT perfusion imaging. In comparison, a screening head
CT scan has an effective dose equivalent of 1.5 mSv.3 With the
recent interest in using a saline chaser to shorten the duration of
the first transit of the contrast bolus through the brain, the scan
duration for CTP can be reduced to around 25 to 30 s resulting
in an even lower dose of 1.8 to 2.2 mSv.
2. Single versus multiple functional parameters.
While xenon-enhanced computed tomography (XeCT) and single
photon emission computed tomography (SPECT) can only measure
cerebral blood flow (CBF), CTP can simultaneously measure CBF,
cerebral blood volume (CBV) and mean transit time (MTT).
Although the results need to be confirmed in a larger clinical trial,
Wintermark et al5 have shown that CBV and CBF together can be
used to differentiate reversible from non-reversible ischemia. A
corollary of this result is that CBV could be viewed as the surrogate
marker for time since ischemia. In this sense, CTP imaging could
provide a more complete assessment of cerebral ischemia than
either XeCT or SPECT in that both the severity and duration of
ischemia would be assessed.
3. Arterial input function (AIF).
The authors are correct in their conclusion that measure-
ment of the arterial input function from proximal branches of
middle cerebral artery (MCA) or anterior cerebral artery
(ACA) is affected by partial volume averaging (PVA). 6 It is
also true that this PVA effect is more prominent when a distal
MCA, or ACA branches are used for the determination of the
AIF when the slice of interest is higher than the usual one
through the basal ganglia. However, methods are available for
the correction of the PVA effect. We described a method in a
prior publication, which requires an independent calibration
of the scanner,6 and thus may not be convenient to use in
clinical departments. A more convenient method is to refer-
ence the area under the AIF to that of the time-density curve
of a venous sinus in one of the acquired CT slices. The
assumption is that the venous sinus used is large relative to the
limiting spatial resolution of CT scanners (0.67 to 0.71 mm)
for the PVA effect to be negligible. If that is the case, the ratio
of the two areas should give the fraction by which the AIF has
been underestimated due to the PVA effect. This very conve-
nient method has already been implemented in one of the
commercially available CTP imaging software.
4. Mean transit time.
It is stated that the MTT measured by CTP is not “the transit
time through the same volume in which the CBV is determined”
instead it is the transit time between MCA and a venous sinus. In
CTP imaging, the MTT map is determined by the deconvolution
of the AIF and the tissue time-density curve corresponding to
each pixel of the map. The deconvolution determines the impulse
residue function7 for the tissue volume in each pixel and the
transit time through that tissue volume is calculated as the ratio
of the area to the height of the impulse residue function as
prescribed by Meier and Zieler.8,9 It is important to note that the
calculation of MTT in CTP does not involve a deconvolution
between the AIF and the venous sinus time-density curve to
determine the transit time between MCA and the venous sinus.
The venous sinus time-density curve is used just for PVA
correction as discussed above in point #3.
5. Blood–brain barrier disruption.
There is concern that CTP imaging may return erroneous CBF
and CBV values when the blood–brain barrier becomes perme-
able following ischemia. We have extended the basic CTP tracer
kinetics model to account for blood-tissue permeability to con-
trast agent.10 Furthermore, 2 of our prior publications have
validated the extended CTP imaging method in the measurement
of CBF in a brain tumor model11 as well as the measurement of
tumor blood flow in a soft tissue tumor model12 against a gold
standard—microspheres (class I data).
6. Imaging speed.
The characterization by the authors that echoplanar mag-
netic resonance (MR) is faster than CT is a simplification of
a complicated issue. A proper comparison of speed between
CT and MR should include considerations of spatial resolution
and signal-to-noise of the resultant images not just on the raw
speed of image acquisition. As discussed earlier good spatial
resolution is required for PVA correction of the AIF. If we
compare the spatial resolution achieved with CTP with those
of echoplanar MR, then the comparison may not be as
favorable to MR. For instance, an echoplanar T2* weighted
spin-echo imaging sequence can acquire a slab of 11  6 mm
slices every 1.6 s at an in-plane resolution of 4.8 mm (phase
encode [y-] direction) and 1.7 mm (read [x-] direction),
whereas a CTP sequence can acquire a slab of 4  5 mm slices
every 0.5 to 1.0 s at an in-plane resolution of 0.67 to 0.71 mm
in both x and y directions. CTP can measure the time-density
curve from a venous sinus unaffected by the PVA effect. This
is critical for the correction of the PVA effect on the AIF.
Currently used MR echoplanar imaging sequences, because of
its poorer spatial resolution, cannot implement the same
correction method for the PVA effect on the AIF as CTP
imaging can.
Ting-Yim Lee, PhD
Imaging Program
Lawson Health Research Institute and
Imaging Research Laboratories
Robarts Research Institute
London, Ontario, Canada
Vadim Belesky, MD
Clinical Neurosciences
London Health Sciences Centre
London, Ontario, Canada
Paul Kalapos, MD
Donald Lee, MD
Department of Radiology
London Health Sciences Centre
London, Ontario, Canada
Vladimir Hachinski, MD
Clinical Neurosciences
London Health Sciences Centre
London, Ontario, Canada
David Spence, MD
Clinical Neurosciences and
Stroke Prevention and Atherosclerosis Research Centre
Robarts Research Institute
London, Ontario, Canada
Effective Dose Equivalent, mSv Axial Coverage, cm
XeCT* 4.4–6.6 4–6
SPECT† 8.84 Whole head
CTP‡ 3.3 2
*80 kVp, 200 mA, 2s per scan, 1 baseline scan plus 6 post-enhancement
scans for each slice.
†Assume 740 MBq of 99m Tc-HMPAO injected.
‡80 kVp, 190 mA, 1 s per scan, 45 scans per slice.
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T.-Y.L. is the developer of the CT Perfusion software and
Robarts Research Institute is the licensor of the software to
General Electric Medical Systems.
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Speaking for my colleagues in the Writing Group on Perfusion
Imaging from the Council on Cardiovascular Radiology of the
American Heart Association, I would like to make a few points
in response to the excellent, informative letter of Dr. Lee and his
colleagues.
1. In point 2, they state that the combination of computed
tomography perfusion (CTP)-derived cerebral blood volume
(CBV) and cerebral blood flow (CBF) can differentiate revers-
ible from non-reversible ischemia. All neuroscientists would
applaud if that statement were proven to be true. I would suggest
the word, “might”. Animal studies with comparative techniques
acting as gold standards, and much larger controlled clinical
studies will be necessary to ascertain the truth. “Reversibility”
can be either spontaneous or through interventions such as the
administration, intravenously or intra-arterially, of a
thrombolytic agent, among many possibilities. Such treatments
have their own sets of variables that add to the complexity of the
prediction of tissue viability.
The use of CBV plus CBF is similar to the magnetic resonance
(MR) paradigm of using diffusion and perfusion, with CBV
paralleling diffusion, and CBF the perfusion parameter. Similar
problems regarding “reversibility” may confront CTP as they do
with MR perfusion/diffusion imaging. Recent articles suggest
that diffusion as measured with MR is not as simple as initially
thought. Physiologically, a focus of ischemia is heterogeneous.
Within this focus there is a mixture of diffusion values, depen-
dent on a variety of factors, including local collateral flow. This
collateral allows CBV to increase initially as an attempt to
maintain tissue oxygenation, but then the average CBV value
drops as this autoregulatory mechanism fails. While a low CBV
value probably indicates that some infarction is present, how
much? Is any of this process reversible? Is there a population of
cells that can be rescued? Over what time period?
It is said that CBV might be a surrogate marker for “time since
ischemia”. Given the physiological discussion above, it is diffi-
cult to understand that statement. CBV depends on, to a greater
degree, the status of the collateral circulation, not the time since
the insult. It is a reflection of severity—the failure of an
autoregulatory mechanism.
It is also said that CTP can provide a “more complete
assessment” of ischemia than either XeCT or SPECT. By more
complete, the authors mean the multiple calculated parameters.
That may or may not be helpful in making difficult clinical
decisions. As discussed in our article,1 there has been an
extensive experience using CBF as determined with XeCT, a
single quantified value, to predict not only the potential revers-
ibility of the ischemic process, but also the propensity for edema
formation and hemorrhage. SPECT has also demonstrated an
ability to predict hemorrhage with thrombolytic treatment. Thus,
we should insist on “efficacy” of a technique for clinical
utilization, whether that is with one or more parameters, rather
than on the number of variables that can be calculated.
2. In point 5, the authors cite their excellent work on
calculating correction factors to account for a permeable blood–
brain barrier in tumor models. However, a well-defined tumor is
not the same as a heterogeneous region of ischemia/infarction.
3. In point 6, mixing speed of image acquisition with other
parameters such as spatial resolution makes for a very difficult
comparison of perfusion techniques. Contrast resolution, with
MR leading the other methodologies reviewed, could be added to
the equation, too. The message we attempted to convey is that
MR permits imaging of the whole brain, whereas current
quantitative CT methodologies are limited to a relatively small
field of view within the defined region of interest.
Richard E. Latchaw, MD
Department of Radiology, Section of Neuroradiology,
University of California at Davis
Davis, California
1. Latchaw RE, Yonas H, Hunter GJ, Yuh WTC, Ueda T, Sorensen AG,
Sunshine JL, Biller J, Wechsler L, Higashida R, Hademenos G.
Guidelines and recommendations for perfusion imaging in cerebral is-
chemia. Stroke. 2003;34:1084–1104.
Cellular-Fibronectin and Matrix
Metalloproteinase-9 in Patients With Stroke
To the Editor:
The article by Castellanos et al on the plasma cellular-
fibronectin (c-Fn) and matrix metalloproteinase-9 (MMP-9)
concentrations in patients with acute ischemic stroke needs some
clarification.1
In the Materials and Methods section it is stated that plasma
MMP-9 levels were measured by a commercially available
ELISA assay. The Amersham Biosciences, from which the assay
was purchased, provides different types of assay for determina-
tion of MMP-9. One of them is for human MMP-9 and measures
both free pro-MMP-9 and pro-MMP-9 complexed to TIMP-1.
The other method, called MMP-9 activity assay, is used for
determination of the active form of the compound.
It is not clear which form of MMP-9 was determined in the
study. The MMP-9 human assay’s range of detection in plasma
is 4 to 128 ng/mL, whereas the median values obtained in the
study were within the range of 54 to 225 ng/mL. We therefore
guess that the authors did not measure the active form of the
enzyme because the assay range is much lower, 0.5 to 16 ng/mL.
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This could have given different results as to the changes in
proteolytic activity, in agreement with findings in a study by our
group.2
In our study the total (pro-, active and complexed) concentra-
tions of MMP-9 were significantly higher in peritoneal fluid of
women with endometriosis (reproductive-age inflammation-
associated disease of women) than of healthy controls. No
differences between the 2 groups were found in the concentra-
tions of the active form of the compound. We suggested it was
due to the presence of a pro-MMP-9 form and possibly attenu-
ation of the pro-MMP-9 activation processes in peritoneal fluid.2
Castellanos et al1 found that c-Fn was a more specific marker
of high risk for cellular hemorrhage and thrombosis. We are in
agreement with the authors that increased c-Fn synthesis could
be an attempt to decrease endothelial destruction by MMPs.
However, we doubt that this explains the positive correlation
found between c-Fn and MMP-9. We believe this conclusion
would be better founded if activity of the enzyme was measured
with the appropriate method.
P. Laudanski, MD, PhD
Department of Pathophysiology of Pregnancy
J. Szamatowicz, MD, PhD
Department of Gynecology
H. Laudanska, MD, PhD
Department of Dermatology
Medical University of Bialystok
Bialystok, Poland
1. Castellanos M, Rogelio L, Serena J, Blanco M, Pedraza S, Castillo J,
Da`valos A. Plasma cellular-fibronectin concentration predicts hemor-
rhagic transformation after thrombolytic therapy in acute ischemic stroke.
Stroke. 2004;35:1671–1676.
2. Szamatowicz J, Laudanski P, Tomaszewska I. Matrix metalloproteinase-9
and tissue inhibitor of matrix metalloproteinase-1: a possible role in the
pathogenesis of endometriosis. Hum Reprod. 2002;17:284–288.
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We thank Drs Laudanski, Szamatowicz, and Laudanska for
their comments on our article.1
In our study we determined both free pro-metalloproteinase-9
(MMP-9) and pro-MMP-9 complexed to TIMP-1 using the
appropriate Amersham Biosciences ELISA assay kit and so
Laudanski and colleagues are right that we have not indepen-
dently analyzed the MMP-9 active form.1
In Laudanski’s study into the pathogenesis of endometriosis
they analyzed both the complexed and the active form of MMP-9
separately, obtaining different levels of the molecule, which
allowed them to conclude that there was a disturbed equilibrium
between MMP-9 and TIMP-1 in the peritoneal fluid of women
with endometriosis.2 In our study we aimed to investigate
whether high plasma levels of cellular-fibronectin (c-Fn) and
MMP-9 were related to hemorrhagic transformation (HT) in
patients with ischemic stroke who had received thrombolytic
treatment. As we analyzed the active form together with the
complexed MMP-9 levels, we are not able to determine whether
a possible imbalance between MMP-9 and its inhibitor might be
related to HT in our patients. However, it has recently been
demonstrated that only the active MMP-9 form participates in the
degradation of the components of the extracellular matrix in an
experimental model of cerebral ischemia,3 and so we can
hypothesize that the difference in the levels of MMP-9 between
patients with and without HT are due to higher levels of the
active form. As Laudanski et al suggest, further analysis of both
molecules would give us a better understanding of the mecha-
nisms participating in the development of bleeding after cerebral
ischemia, and until such a study is performed we can only
speculate as to how the c-Fn/MMP-9 positive correlation is to be
explained.
Independently of what the precise mechanism may be, our
findings demonstrate that high levels of both molecules predict
subsequent bleeding in our stroke patients and so has the
potential to be of great practical value.
Mar Castellanos, MD, PhD
Department of Neurology
Hospital Universitari Doctor Josep Trueta
Girona, Spain
Jose´ Castillo, MD, PhD
Hospital Clı´nico Universitario Santiago de Compostela
Santiago de Compostela, Spain
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GJ. Focal cerebral ischemia induces active proteases that degrade micro-
vascular matrix. Stroke. 2004;35:998–1004.
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